Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Abstract Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibi...